Targeting histone deacetylases in pancreatic ductal adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC) is a dismal disease with a median survival below 6 months and a 5-year survival rate below 1%. Effective therapies for locally advanced or metastatic tumours are missing and curatively resected patients relapse in over 80% of the cases. Although histone deacet...

Descripción completa

Detalles Bibliográficos
Autores principales: Schneider, Günter, Krämer, Oliver H, Fritsche, Petra, Schüler, Susanne, Schmid, Roland M, Saur, Dieter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2010
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3828843/
https://www.ncbi.nlm.nih.gov/pubmed/19929947
http://dx.doi.org/10.1111/j.1582-4934.2009.00974.x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3828843/
https://www.ncbi.nlm.nih.gov/pubmed/19929947
http://dx.doi.org/10.1111/j.1582-4934.2009.00974.x

Ejemplares similares